In vitro and in vivo impacts of nifedipine and diltiazem on praziquantel chemotherapy in murine Schistosoma mansoni

Bibliographic Information
Authors: Adel Madbouly N.; Emam M.; Ayman M.; Ayman M.; Rabia I.; El Amir A.
Journal: Experimental Parasitology
Publisher: Academic Press Inc.
Publication Date: May 2022
Volume / Issue: Volume 236-237
Article No.: 108256
ISSN: 144894
DOI: 10.1016/j.exppara.2022.108256
Scopus: View on Scopus
PubMed: 35398100
Document Type: Article
Authors and Affiliations
Adel Madbouly N., Zoology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt; Emam M., Faculty of Biotechnology, October University for Modern Science and Arts (MSA), 6th October City, Giza, Egypt; Ayman M., Faculty of Biotechnology, October University for Modern Science and Arts (MSA), 6th October City, Giza, Egypt; Ayman M., Faculty of Biotechnology, October University for Modern Science and Arts (MSA), 6th October City, Giza, Egypt; Rabia I., Department of Parasitology, Theodore Bilharz Research Institute, Giza, Egypt; El Amir A., Zoology Department, Faculty of Science, Cairo University, Giza, 12613, Egypt
Abstract
Aim: This study was planned to evaluate the in vitro and in vivo antischistosomal effects of the widely used antihypertensive drugs, nifedipine (NIF) and diltiazem (DTZ), and their combinations with praziquantel (PZQ) on early and late Schistosoma (S.) mansoni infections 21- and 45- days old stages. Methods: In the In vitro study, Calcium channel blockers (CCBs), NIF and DTZ were added to schistosomula and adult worm cultures in different concentrations 10, 20 and 30 mg/ml. The mortality percentage was calculated 1, 12 and 24 h after incubation. In vivo, NIF and DTZ either alone or combined with PZQ were used to treat male albino mice. The parasitological and total immunoglobulin (Ig) G and IgM anti-soluble egg antigen (SEA) were assessed to demonstrate the disease severity. Results: In the In vitro study, 10 mg/ml NIF induced 100% mortality percentage of both schistosomula and adult worms after 24 h incubation, while DTZ induced similar mortality percentage at 30 mg/ml concentration. In vivo results showed that early or late combination of 30 mg/kg of NIF, but not DTZ, significantly (P <0.05) enhanced the reductive efficacy of PZQ based on the parasitological data. The maximal reduction (P <0.05) of anti-SEA IgM and IgG levels was developed during NIF-PZQ administration 21- (1.12 ± 0.06 and 1.09 ± 0.04, respectively) or 45- (1.00 ± 0.03 and 0.8 ± 0.06, respectively) days post infection (PI), compared to either PZQ or NIF individual treatments. The decreased concentration of anti-SEA antibodies was correlated with the diminished granulomatous diameter and disease severity. Conclusion: Nifedipine improved PZQ chemotherapy targeting either early or late S. mansoni infection in mice compared to the PZQ mono-therapy. Administering NIF can be considered as a promising drug candidate for schistosomiasis chemotherapy. © 2022
Keywords
Diltiazem; Murine; Nifedipine; Praziquantel; S. mansoni; Sm.TRPM<sub>PZQ</sub>; Animals; Anthelmintics; Immunoglobulin G; Immunoglobulin M; Male; Mice; Schistosoma mansoni; Schistosomiasis mansoni; delay tiazem; epilat; transient receptor potential channel M; anthelmintic agent; adult; animal experiment; animal model; animal tissue; antibody detection; Article; calcium transport; controlled study; disease severity; drug efficacy; drug safety; immunoassay; immunoglobulin blood level; in vitro study; in vivo study; mouse; nonhuman; stereomicroscopy; animal
Citation Information
Scopus Citations: 2
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
